Posterior reversible encephalopathy syndrome associated with dose-adjusted EPOCH chemotherapy

Conclusion To our knowledge, this is the first description of PRES associated with DA-EPOCH. Key risk factors for development of PRES identified in our study include hypertension, fluid imbalance, electrolyte abnormalities, baseline organ dysfunction, high tumor burden and presence of preexisting CNS insults during chemotherapy treatment such as CNS infection. Patients with these risk factors appear to be at higher risk of developing PRES and should be monitored closely during treatment. Teaser The purpose of our study was to identify risk factors for development of posterior reversible encephalopathy syndrome (PRES) following administration of DA-EPOCH. Out of 44 patients receiving DA-EPOCH at our institution, 3 (7%) were diagnosed with PRES. Patients who developed PRES were more likely to have a preexisting CNS insult, fluid status or electrolytes abnormalities, and hypertension.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research